Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with induction TPF followed by cisplatin- or carboplatin-based chemoradiation in unresectable head and neck cancer
NL-OMON32191Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, cisplatin, carboplatin, docetaxel and fluorouracil in head and neck squamous cell carcinoma (HNSCC) and laryngeal cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Feasibility. Started Jan 2009; status: active, not recruiting.
02
Drugs
cetuximabcisplatincarboplatindocetaxelfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)laryngeal cancer
Beyond the preview
Go deeper on NL-OMON32191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32191.